

Supplementary Table S2. Hematological and biochemical parameters for efficacy study

Parameters	HC-Ad-TK + HC-Ad.TetOn.mCMV.hsFit3L		
	90 dpi Survivor	120 dpi Re-Challenged Survivors	
	Values	Mean	Range
RBC (M/uL)	9.0	9.3	8.8-9.81
Hemoglobin (g/dL)	16.1	16.3	15.5-17.1
Hematocrit (HCT %) (PCV)	45.8	47.1	44.9-49.4
Mean Corpuscular Volume (MCV fL)	50.8	50.7	50.4-51
MCH (pg)	17.9	17.5	17.2-17.9
Mean Cell Hemoglobin Concentration (MCHC g/dL)	35.2	34.6	34.2-35.2
RDW-SD (fL)	28.3	28.3	27.7-28.7
RDW-CV (%)	22.4	22.7	22.3-23.4
Reticulocytes (K/uL)	275.7	249.6	225.6-275.7
Reticulocytes (%)	3.1	2.7	2.3-3.06
Platelets (K/uL)	559.0	575.5	552-610
PDW (Platelet Distribution Width fL)	9.9	9.4	9-9.9
MPV (Mean Platelet Volume fL)	7.5	7.5	7.5-7.5
P-LCR (Platelet Larger Cell Ratio %)	10.2	10.1	9.7-10.2
PCT (Plateletcrit %)	0.4	0.4	0.41-0.46
WBC (K/uL)	6.4	6.6	6.13-7.39
Neutrophils (K/uL)	0.6	0.6	0.43-0.82
Lymphocytes (K/uL)	5.3	5.5	4.93-6.51
Monocytes (K/uL)	0.4	0.4	0.36-0.44
Eosinophils (K/uL)	0.0	0.0	0.01-0.01
Basophils (K/uL)	0.0	0.0	0.01-0.01
Neutrophils (%)	9.7	10.0	5.9-13.3
Lymphocytes (%)	83.0	83.7	80.4-88.1
Monocytes (%)	6.9	6.1	5.6-6.9
Eosinophils (%)	0.2	0.2	0.1-0.2
Basophils (%)	0.2	0.2	0.1-0.2
Glucose (mg/dL)	213.0	219.8	165-253
BUN (Blood Urea Nitrogen mg/dL)	19.0	17.8	16-19
CRE (Creatinine mg/dL)	0.4	0.4	0.4-0.4
PHOS (Phosphorus mg/dL)	6.4	7.6	6.4-8.4
CA (Calcium mg/dL)	9.6	10.2	9.6-10.5
TP (Total Protein g/dL)	5.0	5.3	5-5.4
ALB (Albumin g/dL)	2.5	2.6	2.5-2.7
GLOB (Globulin g/dL)	2.5	2.7	2.5-2.8
ALT (Alanine Aminotransferase U/L)	38.0	54.0	38-69
ALP (Alkaline Phosphatase U/L)	310.0	280.0	261-310
TBIL (Total Bilirubin mg/dL)	0.1	0.1	0.1-0.1
CHOL (Cholesterol mg/dL)	66.0	77.8	66-86
AMYL (Amylase U/L)	1,361.0	1,194.3	1,107-1,361
AST (Aspartate Aminotransferase U/L)	64.0	99.5	59-211

Blood and sera were evaluated to determine the safety of allometrically scaled doses of DOX in rats for 1 month in animals bearing brain tumors. Animals were analyzed 90 days after the gene therapy to treat the primary brain tumor, and 120 days after gene therapy (30 days after a secondary tumor implantation).